{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Christchurch", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberConstituency=Christchurch", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Christchurch&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&tablingMemberConstituency=Christchurch", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Christchurch", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Christchurch", "items" : [{"_about" : "http://data.parliament.uk/resources/1732828", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1732828/answer", "answerText" : {"_value" : "
The Medicines and Health products Regulatory Agency may authorise a line extension, which is a new product authorisation linked to the original marketing authorisation. Various versions of the COVID-19 vaccines have been approved as line extensions to the original vaccines since the first COVID-19 vaccines were approved in December 2020. Variations may be requested to add an indication, dosage form, strength or pack size, which will make the vaccine available for a wider patient pool, whilst maintaining effectiveness and an acceptable safety level. For example, Pfizer, in late 2021, made an application to extend the indication of their vaccines to children between five and 11 years old in a smaller 10 micrograms per dose, and later, via the European Commission Decision Reliance Procedure, a new three micrograms per dose in infants and children between aged six months and four years old. New versions of the vaccine have also been introduced to adapt the vaccines to the new strains of the virus.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"} } , "answeringMemberConstituency" : {"_value" : "Gorton and Denton"} , "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"} , "dateOfAnswer" : {"_value" : "2024-10-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-14T15:31:33.96Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-09", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what modifications have been made to existing Covid-19 vaccine products; for what reasons were those modifications made; and when those modifications were approved by the Medicines and Healthcare Products Regulatory Agency.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"} } , "tablingMemberConstituency" : {"_value" : "Christchurch"} , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"} ], "uin" : "8098"} , {"_about" : "http://data.parliament.uk/resources/1732829", "AnsweringBody" : [{"_value" : "Treasury"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1732829/answer", "answerText" : {"_value" : "
On 29 July, the Government announced that, as of 1 January 2025, all education services and vocational training provided by a private school in the UK for a charge will be subject to VAT at the standard rate of 20 per cent. This will also apply to boarding services provided by private schools.<\/p>
<\/p>
A technical note setting out the details of the policy has been published online here: https://www.gov.uk/government/publications/vat-on-private-school-fees-removing-the-charitable-rates-relief-for-private-schools(opens in a new tab)<\/a>.<\/p> <\/p> Draft VAT legislation was also published alongside this technical note, forming a technical consultation, which closed on 15 September. As part of this technical consultation, the Government engaged with a broad range of stakeholders.<\/p> <\/p> Whilst developing these policies, the Government has carefully considered the impact that they will have on pupils and their families across both the state and private sector, as well as the impact they will have on state and private schools. Following scrutiny of the Government's costings by the independent Office for Budget Responsibility (OBR), details of the Government\u2019s assessment of the expected impacts of these policy changes will be published at the Budget on 30 October in a Tax Information and Impact Note.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4797", "label" : {"_value" : "Biography information for James Murray"}
}
, "answeringMemberConstituency" : {"_value" : "Ealing North"}
, "answeringMemberPrinted" : {"_value" : "James Murray"}
, "dateOfAnswer" : {"_value" : "2024-10-14", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-10-14T14:23:29.893Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "14"}
, "answeringDeptShortName" : {"_value" : "Treasury"}
, "answeringDeptSortName" : {"_value" : "Treasury"}
, "date" : {"_value" : "2024-10-09", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Church Schools: VAT"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Chancellor of the Exchequer, what assessment she has made on the potential impact of VAT on private school fees on Christian schools.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
}
, "tablingMemberConstituency" : {"_value" : "Christchurch"}
, "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
], "uin" : "8099"}
, {"_about" : "http://data.parliament.uk/resources/1732830", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1732830/answer", "answerText" : {"_value" : " The Medicine and Healthcare products Regulatory Agency uses both observed and expected analysis in their assessment of safety signals for COVID-19 vaccines. Data obtained from the spontaneous Yellow Card reporting system, through which patients, public and healthcare professionals can report any incident associated with a medical product, was used to calculate \u2018Observed\u2019 figures. Estimated \u2018Expected\u2019 figures for pre-determined events were based on the total number of patients who had received the vaccine and the background rate of the event within a pre-pandemic period, using large electronic healthcare record databases. It should be recognised that the purpose of observed versus expected analyses is not to confirm the presence, absence, or magnitude of risks but to provide an alternative approach to rapid signal detection, in addition to disproportionality approaches, to maximise the value of spontaneous reports.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
, "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
, "dateOfAnswer" : {"_value" : "2024-10-14", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-10-14T15:32:45.277Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-10-09", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, for what reason the MHRA uses observed analyses instead of expected analyses in assessing the safety of Covid-19 vaccines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
}
, "tablingMemberConstituency" : {"_value" : "Christchurch"}
, "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
], "uin" : "8100"}
, {"_about" : "http://data.parliament.uk/resources/1732831", "AnsweringBody" : [{"_value" : "Ministry of Justice"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1732831/answer", "answerText" : {"_value" : " Nationality data held by courts is not held centrally by the Ministry of Justice. We are therefore unable to provide information on how many Albanian nationals have been sentenced to imprisonment at court in the last 12 months. We have instead provided information on sentenced prison admissions for Albanian nationals between April 2023 and March 2024 (the latest 12 months published period). This information has been provided in the data attached.<\/p>